Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.
Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy...
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, November 10, 2026Time:8:30 am Easter
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and site selections for Phase 3 confirmatory randomized clinical trial in post-first line, post-BTKi population evaluating Progression-Free Survival as primary endpoint underway; dosing of first patients expected in 1Q27 and application for U.S. accelerated market approval anticipated
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
This is the newest page. Registered accounts read further back.